本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
LONDON, July 12, 2023 /PRNewswire/ -- Johnson Matthey (JM), a global leader in sustainable technologies, has today signed an investment agreement with the Jiading District in Shanghai to help accelerate the hydrogen economy in China. Johnson Matthey signs agreement for hydrogen investment in China At a signing ceremony in Sonning, UK today, JM and the Shanghai Jiading District announced plans to build a new catalyst coated membrane (CCM) production facility, providing CCM production capability for multiple proton exchange membrane (PEM) fuel cell applications and PEM electrolysers. The facility which will have an initial capacity of up to 5GW, will occupy 22,000m2 in the Jiading district of Shanghai, in a designated Hydrogen industrial zone and is due to be operational in 2025. It will have potential to expand further in line with customer demand. The investment, which is backed by customer demand, is part of JM's £1.1 billion global stated capital expenditure for the three years to 2024/25 and will include government support and incentives. Dr Mark Su, President of Greater China at Johnson Matthey, said: "This is a landmark investment for our business as we build our footprint in the US, Europe and now China, cementing our presence in all three major hydrogen markets. We are excited to expand our businesses whilst creating and scaling the low carbon solutions that will help China achieve carbon neutrality by 2060." The new production facility will enable Johnson Matthey to supply existing Chinese and international customers with locally produced CCMs, and in addition there is a strong pipeline of further customer interest across both fuel cell and renewable (green) hydrogen technologies. Ms. Gao Xiang, Mayor of Jiading District, said: "Jiading District is a famous international automobile city and one of the earliest areas in China to develop a hydrogen industry. With the help of companies like Johnson Matthey, we are able to actively build a hydrogen technologies innovation hub and a national fuel cell vehicle demonstration city. This investment agreement plays to both parties' strengths and is a win-win cooperation." CCMs are key performance defining components in fuel cell electric vehicles (FCEV). China has said it aims to have 1 million hydrogen-powered vehicles on its road by 2030. Johnson Matthey has a long heritage in China with six state-of-the art manufacturing facilities. JM is one of China's leading auto catalyst producers and platinum group metals traders and refiners, and a leading player across syngas and hydrogen fuel cells. JM was the first commercial scale membrane electrode assembly (MEA) producer in China, producing the MEAs for hydrogen fuel cell shuttle buses showcased in the Beijing Winter Olympics 2022. Johnson Matthey is a global leader in sustainable technologies, catalysing the net zero transition. With over 200 years of sustained commitment to innovation and technological breakthroughs, we improve the performance, function and safety of our customers' products. Our science has a global impact in areas such as low emission transport, energy, chemical processing and making the most efficient use of the planet's natural resources. Today, about 13,000 Johnson Matthey professionals collaborate with our network of customers and partners to make a real difference to the world around us. For more information visit www.matthey.com
MACAO, July 12, 2023 /PRNewswire/ -- The 2023 World Cities Branding Conference opened at the MGM Cotai in Macao, China, on July 3. Government officials, industry experts and guest speakers across the world exchanged views on city branding, cultural exchanges, tourism and sustainable urban development. The conference was founded to support Chinese cities to build their branding and find new growth momentum in the cultural and tourism sector. The event also unveiled the 2023 Great Wall Award - Culture & Tourism Branding Award, with the trending BBQ of Zibo City in Shandong Province winning the gold medal, among 50 outstanding cases of the year. World Cities Branding Conference opens in China’s Macao The first World Cities Branding Conference is initiated and organized by the Organizing Committee of the World Cities Branding Conference, and co-hosted by the World Tourism Economy Research Center. Phoenix New Media organized the event. MGM is also the chief partner and the official venue provider. And HONDA INSPIRE is the goodwill partner. The conference is supported by the Macao Government Tourism Office and Macao Trade and Investment Promotion Institute. China Advertising Association and Communication University of China School of Advertisement, along with many other research institutes, join hands in developing this world-level international forum focusing on branding for cultural and tourism industries. Lei Wai Nong, Representative of the Chief Executive of the Macao Special Administrative Region and the Secretary for Economy and Finance of the Macao SAR government; Pansy Ho, Chairman of the Global Tourism Economy Research Centre and Group Executive Chairman and Managing Director of Shun Tak Holdings Limited; Yang Hao, Deputy Director of the Economic Department of the Liaison Office of the Central People's Government in the Macao SAR.; Vincent U U Sang, President of Macao Trade and Investment Promotion Institute; Sun Yusheng, Executive Director and Editor-in-Chief of Phoenix Media Investment (Holdings) Limited and Chairman of the Board of Directors and Chief Executive Officer of Phoenix New Media Limited; Zhang Guohua, President of China Advertising Association and Vice President of International Advertising Association; and Ding Junjie, Professor of Communication University of China and Director of the National Institute of Advertising, attended and spoke at the conference. Kenneth Feng, President, Strategic and CFO of MGM, also joined the event. H.E. Mr. Arthayudh Srisamoot, Ambassador of Thailand to China; H.E. Mr. Alain Wong, Ambassador of Mauritius to China; H.E. Mr.John Busuttil, Ambassador of Malta to China; Patrick Nijs, Former Ambassador of Belgium to China; and Souad Zaidi, General Secretary of the Moroccan Association of mayors and Former Member of Moroccan Parliament; Robert Govers, Founding Chairman of the Internationa Place Branding Association (IPBA); John D Chacko, Global VP of International Advertising Association and Chairman of IAA World Congress 2024 also attended and spoke at the event. Wu Hongbo, Former Deputy Secretary-General of the United Nations and Honorary President of China International Public Relations Association; Hae-Guk HWANG, Regional Director for Asia and the Pacific at the World Tourism Organization, and Shan Jixiang, Chairman of the China Cultural Relics Academy and Former Director of the Palace Museum, also gave video speeches at the opening ceremony. During the two-day conference, experts from across the world spoke at the event and shared their insights, including Denis Bax, Chief of the Communication, Cities and Events (CCE) Unit and Secretary of the UNESCO Creative Cities Network; David Aaker, "Father of Modern Branding", the Vice-Chair of Prophet Consulting Firm; Zhang Hui, Member of the "14th Five-Year Plan" National Development Planning Expert Committee of the Ministry of Culture and Tourism and Deputy Director of the Expert Committee of World Tourism Cities Federation; Maria Helena de Senna Fernandes, Director of Macao Government Tourism Office; Ouyang Changlin, Director of the Live Streaming Committee of CTAA and The former president of Hunan Broadcasting System; Robert Govers, Founding Chairman of the Internationa Place Branding Association (IPBA); Ray Ng, Executive Chairman of The Industry and Commerce Association of Macau; Ji Xiaodong, President of the China Chamber of Tourism (CCT); Prof. Wu Bihu from Peking University; and Yang Jie, Vice Chairman of Beijing ByteDance Charity Foundation. Lei Wai Nong, Representative of the Chief Executive of the Macao Special Administrative Region and the Secretary for Economy and Finance of the Macao SAR government, said the founding of the World Cities Branding Conference is important, as this platform is key for cities across the world to exchange ideas, empower global engagement and promote people-to-people exchanges, to explore new opportunities. He added that the traditionally strong-branded cities need to speed up on urban renewal, working together with emerging cities, and share development opportunities. Pansy Ho, the Chairman of the Global Tourism Economy Research Centre and Group Executive Chairman and Managing Director of Shun Tak Holdings Limited, expressed her aspirations during her speech. She emphasized the importance of Chinese cultural and tourism brands showcasing their exceptional qualities on a global platform, with the ultimate goal of becoming internationally recognized brands. Furthermore, she shared valuable insights regarding the Global Tourism Economy Forum, a global forum that she initiated in Macao, which has served as a pivotal platform for the global cultural and tourism industry to gain a deeper understanding of the authentic China over the past decade. Sun Yusheng, Executive Director and Editor-in-Chief of Phoenix Media Investment (Holdings) Limited and Chairman of the Board of Directors and Chief Executive Officer of Phoenix New Media Limited said as China undergoes urbanization, Chinese cities shall figure out their very own characteristics and charisma. Sun said he hoped Phoenix Satellite TV and Phoenix New Media can play their unique roles in helping cities shape their branding. At the conference, two academic reports were launched, including the China Area Branding Value Report, presented by Prof. Ding Junjie of Communication University of China, also Director of the National Institute of Advertising, and the 2023 World Cities Branding Index Report, jointly presented by Zhang Tingting, Executive Chairman of the World Cities Branding Conference, also the Director of the Tourism Communication Research Center of the Advertising School at the communication university of China, and Scott Chen, Managing Director of Brand Finance China. The index covers 7 pillars including commercial and trade, livability, cultural heritage, people's values, sustainability & transportation accessibility, governance, and education & science. Industry experts, government officials also joined a series of high-level round-table dialogues featuring a variety of topics, including "Promoting mutual cultural learning through city branding", "Building the soft power of sustainable development of world cities with brands", "Innovate Macao's cultural and tourism brand by content creation", "World-level tourism cities branding development and communication", "Youth design and city development", "Opportunities and challenges for high-quality development of China's county culture and tourism", "Building Lushan as a world-class tourism destination", "City creativity and international communication", etc. Among these forums, government officials from Zhangjiakou City of Hebei Province, and Lushan City of Jiangxi Province, Tahe County of Heilongjiang Province, and Argara of Morocco shared their insights and experiences about on how to build good city branding at a panel discussion moderated by Xu Yue, co-initiator of the World Cities Branding Conference and Director of Culture and Tourism Communication at Phoenix New Media. On July 4, a forum themed "MGM Dialogue: Rediscover the Value of Macao" focused on the branding development of Macao and the city's culture and tourism industry development, with experts from across sectors sharing their opinions. Maria Helena de Senna Fernandes, Director of Macao Government Tourism Office, said it is important to explore effective marketing and communication campaigns to allow more tourists and general public from across the world to learn and understand the wonderfulness and uniqueness of Macao, a world-renowned tourism destination. Phoenix New Media also launched a brand new IP "Let the World Fall in Love with Chinese Cities". The initiative will work with over 100 Chinese cities to better showcase their culture and tourism branding and offerings to the world, on the platforms of the Phoenix media and social platforms. The event also unveiled the gold, silver and bronze awards for the Annual Good Culture and Tourism Award, a special selection of the renowned Great Wall Award. This was the first ranking of top 50 outstanding cases by the conference, covering 5 areas of best cases for branding communication and campaigns.
BOSTON, July 12, 2023 /PRNewswire/ -- Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr. Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. With expertise in modern synthetic chemistry, Medicilon excels in various cutting-edge areas of pharmaceutical research, including chiral drugs, glycochemistry, antibodies and antibody-drug conjugates (ADC), nucleoside/nucleotide drugs, and oligonucleotide drugs (such as RNAi). Additionally, Medicilon has made significant advancements in PROTAC technology and enhanced its BSL-2 laboratory facility. With the growing pharmaceutical industry and the widespread adoption of artificial intelligence, the market potential for drug discovery is enormous. The addition of Dr. Liu Jian, a seasoned pharmaceutical research scientist, will empower Medicilon Drug Discovery division to revolutionize drug discovery model and bring new imagination to drug discovery. Dr. LIU Dr. Liu Jian obtained his Ph.D. in Computational Chemistry and Organic Chemistry from the University of California, Los Angeles (UCLA), he subsequently conducted postdoctoral research at the University of California, Irvine, and the University of Pennsylvania. In 2018, Dr. Liu Jian served as the President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently the Chairman of the board of directors of SAPA. In 2019, he was awarded the "Outstanding 50 Asian American in Business " by the Asian-American Business Development Center in New York and was elected as one of the 12 most influential Chinese-Americans in New jersey. With over 20 years of experience in innovative drug development, Dr. Liu Jian has led the team to invent 10 preclinical candidates (PCCs), which have entered Phase I, II, and III clinical trials. He has filed over 72 patent applications, with 21 patents already granted. Dr. Liu Jian also possesses profound academic achievements, having published a total of 47 articles in international academic journals and serving as a reviewer for several international academic journals. Dr. Liu Jian joined the industry in 2001 and has worked for Merck for nearly 20 years. He has led the R&D of novel small molecule drugs for various diseases, including osteoporosis, obesity, diabetes, cardiovascular disease, cancer, immune disease, antiviral and antibacterial, and pain. Throughout his career, he progressed from Senior Research Chemist to Principal Scientist and External Discovery Chemistry Lead, receiving the "Merck Excellence Award" four times. He later served as CSO and Operations Director at Jiangsu Hengrui Pharmaceutical USA Drug Discovery Center (EBI), leading the development of new drugs for cancer, immune diseases, osteoarthritis, and neurodegenerative diseases. Recently, he became the CEO of Silexon AI, responsible for building the company's artificial intelligence platform and empowering innovative drug research. Dr. Liu Jian expressed his honor to be part of Medicilon as President of Drug Discovery Division. Medicilon is known for establishing a comprehensive pharmaceutical preclinical research and development service platform in China and cultivated for 19 years. It has prioritized global cutting-edge technologies and fostered technological innovation. Moving forward, Dr. Liu aims to lead the Drug Discovery Division in efficient and high-quality new drug development. This includes establishing and enhancing various technical platforms for innovative drug research such as AIDD and structural biology, peptide and cyclic peptide drug development, synthetic biology, and nuclear medicine development, realizing Medicilon one-stop service experiment from target research recommendation to IND application, we could empower the discovery of more innovative drugs. Dr. Chen Chunlin, the Founder and CEO of Medicilon, said, "Welcome Dr. Liu Jian to join Medicilon. We believe that his extensive academic background, outstanding leadership and rich R&D experience will bring Medicilon more professional and cutting-edge innovative drug development technology , as well as advanced industry insights and strategic guidance crucial to Medicilon to next stage of development. About Medicilon: Medicilon was established in 2004. It is a leading CRO specializing in comprehensive preclinical research and development services in the field of biomedicine. It has established a comprehensive service; technology platform, which integrates compound synthesis, compound activity screening, structural biology, CMC, pharmacodynamics evaluation, pharmacokinetics and toxicological safety evaluation. On November 5, 2019, Medicilon was officially listed on the Science and Technology Innovation Board, becoming the first pharmaceutical CRO company to be listed on the board (Stock Code: 688202.SH). For more information, please visit: http://www.medicilon.com
Global household appliances manufacturer Arçelik simplifies online sales process for trade customers and partners ISTANBUL, July 12, 2023 /PRNewswire/ -- Arçelik A. Ş. (ARCLK: IST, "Arçelik"), the global leading consumer durables and electronics manufacturer has launched MARS, an online commerce platform to enhance sales operations and provide a seamless experience for trade partners. Utku Barış Pazar, Arçelik Chief Strategy and Digital Officer The MARS platform digitalizes manual orders, made through phone, fax, and email, to provide an efficient and seamless B2C-like customer experience for trade partners. The platform streamlines commerce processes among all Arçelik Global subsidiaries, providing faster fulfilment for sales orders, and boosting visibility with a channel where customers can easily access related data and support 24/7, helping drive efficiency and robust data security. The new platform will process millions of global product sales that Arçelik receives annually, lifting the heavy operational load on local sales offices which previously manually processed up to 50% of orders. After implementing the MARS portal, Arçelik's subsidiaries reported achievements such as efficiency and simplicity thanks to mobile support, ability to reach physically remote customers and elimination of human errors. With the help of the MARS project, the duration of average order creation is reduced to approximately 1 minute in total from 6. Besides time-saving, the portal provides high visibility of order status, real-time stock levels, customer-based pricing, product images & features, deliveries, invoices, payments, and the total turnover. Mars provides B2B customers with a seamless e-commerce experience encompassing basket creation, checkout, order tracking, pricing, and account monitoring. Previously, around 20% of subsidiary back-office personnel's time was spent manually inputting sales orders received via phone, email, fax, etc. Additionally, Arçelik's sales representatives encountered challenges in collecting around 40% of orders from geographically distant customers. By comparing the time one back-office personnel spent processing a single charge before and after the portal, the operational workload decreased by approximately 80%. Utku Barış Pazar, Chief Strategy & Digital Officer, Arçelik, commented: "We are proud to launch our B2B e-commerce platform to better serve our partners, enhance customer experience and create a reliable, agile, and efficient global distribution network. Innovation is key in fostering ultimately stronger partnerships and facilitating operational improvement, and a streamlined e-commerce platform such as MARS helps do just that. As a major player in the home appliances industry, we will continue to leverage new technologies to transform our operational processes and support business growth." The MARS portal has already been implemented across its partners and has achieved increased customer satisfaction, a decrease in order lead time, improved data security and has contributed to an overall efficiency and simplicity for customers. The portal is live in the following countries USA, Austria, Serbia, South Africa, Spain, Poland, Australia, New Zealand, Egypt, Germany, Czechia, Philippines, Malaysia and Vietnam. ABOUT ARÇELIK With 40,000 employees throughout the world, Arçelik's global operations include subsidiaries in 52 countries, and 30 production facilities in 9 countries and 12 brands (Arçelik, Beko, Grundig, Blomberg, ElektraBregenz, Arctic, Leisure, Flavel, Defy, Altus, Dawlance, Voltas Beko). Arçelik, Europe's second largest white goods company with its market share (based on volumes), reached a consolidated turnover of 7.7 billion Euros in 2022. Arçelik's 30 R&D and Design Centers & Offices across the globe are home to over 2,300 researchers and hold up to 3,000 international registered patent applications to date. In 2022, Arçelik achieved the highest score in the DHP Household Durables category for the 6th year in a row (based on the results dated December 2022) in the Dow Jones Sustainability Index of the S&P Global Corporate Sustainability Assessment. Through its leadership position in sustainability and credible decarbonization roadmap for achieving net zero, Arçelik became the first and only company from its industry to receive the Terra Carta Seal by His Majesty King Charles III. Arçelik's vision is 'Respecting the World, Respected Worldwide.' www.arcelikglobal.com/en
SINGAPORE, July 12, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, together with researchers from the University Medical Center Hamburg-Eppendorf and Technical University of Munich, received Best Presentation Award for the preclinical study of its first-in-class HBs-directed CD3 and CD28 bispecific antibodies – anti-HBs×CD3 and anti-HBs×CD28 – at the EASL Congress 2023. In the study presented, HBV-infected dual humanized mice received a combination of anti-HBs×CD3 and anti-HBs×CD28 antibodies, and after treatment, serum markers, including HBV DNA, HBsAg, and HBeAg, were significantly reduced. A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy. The data showed a significant reduction of all HBV markers, efficient recruitment of T cells to the liver, targeting of HBV-infected hepatocytes, and induction of both cytolytic and cytokine-mediated HBV-specific T cell immunity crucial for viral clearance. Levels of HBV pgRNA, HBV DNA, and cccDNA in the liver dropped significantly, consistent with the decrease of HBV serum parameters, indicating efficient clearance of infected hepatocytes. "Specific re-direction of T cells to the infected hepatocytes in the liver triggering non-cytolytic control of HBV and killing HBsAg+ cells is curial to achieve a sustained HBV cure," said Professor Ulrike Protzer, Director, Institute of Virology at Technical University of Munich / Helmholtz Munich and SCG Scientific Founder. "Treatment of HBV-infected humanized mice with our T-cell engager antibodies resulted in efficient recruitment of human CD4+ and CD8+ T cells into the liver and triggered an effective antiviral immune response", she added. "High levels of circulating HBsAg compromise antiviral immunity in chronic HBV carriers. Our approach demonstrates that T cells activated by antibodies can efficiently target the nuclear cccDNA reservoir despite high levels of baseline circulating HBsAg. Still, the permanently integrated viral DNA can also be targeted", said Dr. Zhang Ke, Chief Scientific Officer of SCG. Hepatitis B is the world's most common liver infection. One in three humans experiences an HBV infection during their lifetime, and almost 300 million people are chronically infected worldwide. Approximately 25% of chronic HBV infections progress to liver cancer, and HBV contributes to an estimated 820,000 deaths annually. Despite commendable efforts in infant vaccination, about 1.5 million individuals contract new HBV infections yearly. Currently, there is no curative treatment available for HBV infection. HBV-specific immune responses are the key to achieving HBV functional cure. To facilitate optimal local T-cell re-direction and activation, two novel T cell-engaging bispecific antibodies, anti-HBs×CD3 and anti-HBs×CD28, have been designed to bridge HBV-infected cells with CD3-expressing and CD28-expressing T cells. The rationale behind the combination of CD3 and CD28 bispecific antibodies stems from the requirement of T cells for dual signalling to achieve full activation. The initial "recognition" signal occurs when the T cell identifies a foreign antigen through its T-cell receptor/CD3 complex. However, activation of cytotoxic T-cell function only occurs upon receiving a secondary "costimulatory" signal, most effectively mediated by the CD28 costimulatory receptor. Anti-HBs×CD3 and anti-HBs×CD28 specifically target HBsAg with strong neutralizing functionality while bridging T cells to HBV-infected hepatocytes and concurrently providing activation through two crucial synergistic signals. "Bispecific antibodies represent a novel and effective approach to treat certain cancers, and we believe this approach could more broadly apply to other disease areas, such as chronic infections. The publication showcases the significant impact of the anti-HBs×CD3 and anti-HBs×CD28 combination approach in driving substantially enhanced T-cell killing of HBV-infected cells, as demonstrated in these sophisticated dual-humanized animal models", said Frank Wang, Chief Executive Officer of SCG. "The results from our first-in-class preclinical PoC study give us confidence in our bispecific development program for infectious diseases, and we eagerly anticipate further exploration and investigation." About SCG Cell Therapy SCG is a leading biotechnology company focusing on developing novel immunotherapies for infections and their associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections to prevent and cure its associated cancers. Established and headquartered in Singapore, SCG combines regional advantages in Singapore, China, and Germany, covering the entire value chain from innovative drug research and discovery manufacturing to clinical development and commercialization. For more information about SCG, please visit us at www.scgcell.com.
上海2023年7月12日 /美通社/ -- 百勝中國有限公司（Yum China Holdings, Inc.，紐約證券交易所股票代碼：YUMC，港交所股票代碼：9987，以下簡稱「百勝中國」或「公司」）宣布，肯德基中國慶祝其在上海第500家門店開業。1989年，上海第一家肯德基餐廳在外灘東風飯店開業。34年後，上海成為中國首個肯德基門店數突破500家的城市。 百勝中國首席執行官屈翠容女士（Joey Wat）表示：「我們很高興在上海實現了這一裡程碑，上海不僅是中國最大的消費市場，也是百勝中國的運營總部所在地。自1987年進入中國以來，我們一直致力於以美食和愉悅的用餐體驗滿足消費者不斷變化的需求。非常榮幸能夠每天為數以數以百萬計的顧客和數以千計的社區提供服務。展望未來，我們堅信在中國我們擁有巨大的機會持續成長和擴張。」 肯德基高度重視企業社會責任，推動社會積極改變。上海第500家肯德基門店融合了品牌多個社會責任舉措： 打造「美食+閱讀」的服務空間，與上海圖書館東館共同攜手開展「小書迷王國」線下獨立閱讀空間，帶領孩子們講繪本故事、開展游戲互動，讓少年兒童學會用不同的角度發現世界。 攜手浦東新區殘聯旗下的公益助殘示范品牌——「譜夢空間」，共同為殘障青年提升自我、實現職業發展、融入社會提供助力，將該門店打造為上海首家肯德基「天使餐廳」。門店采用配有燈光和鳴叫提示功能的設備，方便「天使員工」通過聲音和燈光閃爍提示完成標准操作。此外，門店還提供盲文菜單和手語菜單，為有特殊需要的顧客提供更加便捷和愉悅的用餐體驗。 肯德基是中國領先和最大的快餐品牌之一，截至2023年3月，在全國1,800多個城鎮擁有超過9,200家門店。多年來，肯德基中國一直把菜單創新作為戰略重點。通過在菜單和產品中融合中西特色，肯德基與中國消費者建立了深厚的聯結。今年夏季，肯德基中國發起了「以經典好滋味致老友」懷舊營銷活動，涵蓋9款熱賣至今的肯德基標志產品，如吮指原味雞、葡式蛋撻、新奧爾良烤雞翅、超值全家桶和皮蛋瘦肉粥等。 前瞻性聲明 本新聞稿中包含的「前瞻性聲明」(包括「2023年業績展望」部分的內容)符合1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的意義。我們意圖將所有前瞻性聲明納入1995年《私人證券訴訟改革法案》的安全港條款范圍。前瞻性聲明的特征通常是其與歷史事實或當前事實並不完全相關，而且會包含前瞻性詞語，如「預期」、「期望」、「認為」、「預計」、「可能」、「可以」、「打算」、「相信」、「計劃」、「估計」、「目標」、「預測」、「規劃」、「有望」、「將會」、「繼續」、「應該」、「預測」、「展望」、「致力」或類似術語。這些聲明是基於我們根據我們的經驗和對歷史趨勢、當前條件和預期未來發展的看法，以及我們認為在當時情況下適當和合理的其它因素而做出的當前估計和假設，但我們不能保證這些估計和假設將被證明正確。前瞻性聲明包括但不限於有關百勝中國未來戰略、增長、業務計劃、投資、股息和股份回購計劃、收益、業績和回報的陳述、有關人口和宏觀經濟趨勢的預期影響的陳述、有關新冠肺炎疫情預期影響的陳述、百勝中國業務的恢復速度、有關我們的創新、數字化和外賣能力以及投資對增長的預期影響的陳述以及與百勝中國業務長期驅動力有關的看法。前瞻性聲明並不能保證業績，其本身就存在難以預測的已知和未知風險和不確定性，可能導致我們的實際結果或事件與這些聲明所顯示的結果或事件存在實質性差異。我們不能向您保證我們的任何預測、估計或假設會實現。本新聞稿中的前瞻性聲明僅在本新聞稿發布之日發表，除非法律要求，否則我們不承擔公開更新任何前瞻性聲明以反映後續事件或情況的義務。眾多因素可能導致我們的實際結果或事件與前瞻性聲明所表達或暗示的結果或事件存在實質性差異，包括但不限於：我們是否能夠按照目前預測的時間和數字實現開發目標（如有），我們的營銷活動和產品創新是否成功，我們維護食品安全和質量控制系統的能力，公共衛生狀況的變化（包括新冠肺炎疫情），我們控制成本和費用（包括稅收成本）的能力，以及中國政治、經濟和監管條件的變化。此外，我們目前不知道的或者我們目前認為不重要的其它風險和不確定因素可能會影響任何此類前瞻性聲明的准確性。在評估所有前瞻性聲明時，應了解其內在的不確定性。您應查閱我們向美國證券交易委員會提交的文件（包括我們的10-K表年度報告和後續的10-Q表季度報告中「風險因素」和「管理層對財務狀況和經營業績的討論和分析」部分的內容），以了解可能影響到我們財務業績和其它結果的因素的更多細節。 關於百勝中國 百勝中國是中國最大的餐飲公司， 以「讓生活更有滋味」為使命。公司有超過40萬員工，並在中國1,800個城鎮經營六個品牌超13,000家餐廳。肯德基和必勝客是西式快餐和西式休閒餐飲領域的領先品牌，塔可鍾提供創新墨西哥風味食品。百勝中國亦與百年意大利品牌Lavazza合作，在中國探索及發展Lavazza咖啡概念。公司旗下還有中式餐飲品牌小肥羊和黃記煌。百勝中國擁有世界一流的數字化供應鏈體系，包括覆蓋全國的龐大物流中心網絡和自有供應鏈管理系統。強大的數字化能力和會員計劃讓公司能夠更快觸達顧客，提供更好的服務。作為財富500強企業，百勝中國的願景是成為全球最創新的餐飲先鋒。欲了解更多信息，請訪問 http://ir.yumchina.com。 投資者關系聯系方式： Tel: +86 21 2407 7556 / +852 2267 5801 IR@YumChina.com 媒體聯系方式： Tel: +86 21 2407 7510 Media@YumChina.com
A12 藝術空間
IR
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
